视网膜静脉阻塞继发黄斑水肿的抗VEGF治疗方案的研究进展

Research progress in anti-vascular endothelial growth factor treatment regimens for macular edema secondary to retinal vein occlusion

抗血管内皮生长因子(vascular endothelial growth factor,VEGF)治疗视网膜静脉阻塞(retinal vein occlusion,RVO)继发黄斑水肿(macular edema,ME)的有效性及安全性已得到广泛证实。但抗VEGF治疗方案尚无统一标准。现行的治疗方案主要包括固定治疗方案、按需(pro re nata,PRN)治疗方案、稳定性标准驱使的按需(stabilization criteria-driven PRN)治疗方案、治疗与延长(treat and extend,T&E)方案。近年来不少研究综合比较了各个治疗方案在改善视功能、量化评估疾病活动性、调整随访频率等多个维度的表现,为临床医生提供选择抗VEGF治疗方案的参考依据。本文旨在回顾并总结近年来对抗VEGF药物治疗RVO继发ME的研究,阐述抗VEGF治疗方案的研究进展。

The efficacy and safety of anti-vascular endothelial growth factor(VEGF)in the treatment of macular edema(ME)secondary to retinal vein occlusion(RVO)have been widely confirmed.However,there is no unified standard for anti-VEGF treatment regimens.Current treatment regimens mainly include fixed treatment regimen,pro re nata(PRN)treatment regimen,stabilization criteria-driven PRN treatment regimen,and treat and extend(T&E)regimen.In recent years,many studies have compared different treatment regimens in composite dimensions,including improving visual function,assessing disease activity quantitatively and adjusting the follow-up frequency,to provide clinicians with a reference of choosing anti-VEGF treatment regimens.The purpose of this article is to review and summarize recent researches on anti-VEGF drugs in the treatment of ME secondary to RVO,and to clarify the research progress in the anti-VEGF treatment regimens.